**Supplementary Table 2. Cumulative signs and symptoms of testosterone deficiency in PSPA-nt and PA-nt patients**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **PSPA-nt**  **(n=25)** | **PA-nt**  **(n=61)** | **p** |
| **Overall** |  |  |  |
| At least one | 18 | 24 | 0.0086 |
| At least two | 12 | 11 | 0.0070 |
| Three or more | 5 | 5 | ns |
| **Specific** |  |  |  |
| At least one | 5 | 2 | 0.02 |
| At least two | 1 | 0 | ns |
| Three or more | 0 | 0 | ns |
| **Suggestive** |  |  |  |
| At least one | 17 | 18 | 0.0015 |
| At least two | 6 | 9 | ns |
| Three or more | 2 | 2 | ns |
| **Non specific** |  |  |  |
| At least one | 4 | 9 | ns |
| At least two | 0 | 0 | ns |
| Three or more | 0 | 0 | ns |

PSPA-nt: patients with a prolactin-secreting pituitary adenoma and testosterone levels in the normal range; PA-nt: patients with a non prolactin-secreting pituitary neoplasm and testosterone levels in the normal range. For more detail, please see Table 3 an Patients and Methods section.